Mirum Pharmaceuticals (MIRM) Assets Average (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Assets Average of $866.9 million for Q1 2026, up 27.39% year-over-year from $680.5 million in Q1 2025, and up 6.5% quarter-over-quarter from $814.0 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Assets Average (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Assets Average history runs 8 years deep, the most recent figure standing at $866.9 million for Q1 2026.
- In Q1 2026, Assets Average rose 27.39% year-over-year to $866.9 million; the TTM figure through Mar 2026 stood at $866.9 million (up 27.39% YoY), while the FY2025 annual figure was $756.8 million, up 14.89% from the prior year.
- Assets Average for Q1 2026 stood at $866.9 million, up from $814.0 million in the prior quarter.
- The five-year high for Assets Average was $866.9 million in Q1 2026, with the low at $286.4 million in Q1 2022.
- The 5-year median for Assets Average is $649.3 million (2024), against an average of $568.0 million.
- Peak annual rise in Assets Average reached 89.18% in 2024, while the deepest fall reached 3.19% in 2024.
- Mirum Pharmaceuticals' Assets Average stood at $358.6 million in 2022, then surged by 80.87% to $648.6 million in 2023, then rose by 3.19% to $669.3 million in 2024, then rose by 21.61% to $814.0 million in 2025, then advanced by 6.5% to $866.9 million in 2026.
- Business Quant data shows MIRM's Assets Average at $866.9 million in Q1 2026, $814.0 million in Q4 2025, and $755.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 967.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 967.95 Mn |
| Mar 31, 2026 | 866.86 Mn |
| Dec 31, 2025 | 813.96 Mn |
| Sep 30, 2025 | 755.47 Mn |
| Jun 30, 2025 | 708.04 Mn |
| Mar 31, 2025 | 680.50 Mn |
| Dec 31, 2024 | 669.32 Mn |
| Sep 30, 2024 | 664.32 Mn |
| Jun 30, 2024 | 656.36 Mn |
| Mar 31, 2024 | 649.29 Mn |
| Dec 31, 2023 | 648.63 Mn |
| Sep 30, 2023 | 547.12 Mn |
| Jun 30, 2023 | 388.56 Mn |
| Mar 31, 2023 | 343.22 Mn |
| Dec 31, 2022 | 358.63 Mn |
| Sep 30, 2022 | 330.79 Mn |
| Jun 30, 2022 | 287.69 Mn |
| Mar 31, 2022 | 286.40 Mn |
| Dec 31, 2021 | 264.91 Mn |
| Sep 30, 2021 | 241.42 Mn |